title: MET: a new promising biomarker in non-small-cell lung carcinoma.
abstract: Non-small-cell lung cancer (NSCLC) leads cancer-related deaths worldwide. Mutations in the kinase domain of the EGFR gene provide sensitivity to tyrosine kinase inhibitors (TKI) drugs. TKI show initial response rates over 75% in mutant EGFR-NSCLC patients, although most of these patients acquire resistance to EGFR inhibitors after therapy. EGFR-TKI resistance mechanisms include amplification in MET and its ligand, and also MET mutations. MET signaling dysregulation has been involved in tumor cell growth, survival, migration and invasion, angiogenesis and activation of several pathways, therefore representing an attractive target for anticancer drug development. In this review, we will discuss MET-related mechanisms of EGFR-TKI resistance in NSCLC, as well as the main drugs targeted to inhibit MET pathway.
authors.affiliation: Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda Fuerzas Armadas, 2, 18014 Granada, Spain.
authors.forename: Cristina
authors.initials: C
authors.lastname: Pérez-Ramírez
authors.forename: Marisa
authors.initials: M
authors.lastname: Cañadas-Garre
authors.forename: Enrique
authors.initials: E
authors.lastname: Jiménez-Varo
authors.forename: María José
authors.initials: MJ
authors.lastname: Faus-Dáder
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Calleja-Hernández
mesh_terms: D015415:Biomarkers; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D009154:Mutation / Q000235:genetics; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*
chemical_list: D015415:Biomarkers; D005819:Genetic Markers; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met
keywords: EGFR; MET; TKI; pharmacogenetics; resistance; targeted therapies